When Lilly’s new Bio-Similar insulin for Lantus becomes available for maybe 20% less, will you let your patients know? Follow the link to share your opinion!

For years many of us have lamented the butchering that Dr. Steven Nissen gave to the TZDs. Part of this came from the extra cardiovascular studies that every manufacturer had to do on new diabetes drugs that came to market. Many of you thought that those studies were useless and …

This past weekend, I presented a talk to Consultant Pharmacists, Directors of Nursing, and Medical Directors in Long Term Care. We were focusing on the team approach to diabetes care and how that has changed over the past couple of years. (Part of that presentation is in this week’s Homerun …

I received a call from a physician’s office regarding a patient who needed education as soon as possible. Her A1C had risen to 7.5 and at 64 years old, the patient needed to make changes. The only problem: the patient was blind. The patient lived alone with her Seeing Eye dog and was assisted by her brother. She lived a relatively normal life despite her blindness, working a clerical job and visiting the gym 2 days per week. As an educator, I had never dealt with a truly sightless individual and was feeling ill-equipped to take on this challenge. The majority of the diabetes patients in our small rural clinic have sight enough to manage their disease. I started to think of all the things we take for granted when teaching our patients, such as lancing their fingers, reading a label, even simply putting the correct amount of food on their plate. All that was thrown out the window. How did I help this patient to see her diabetes care?

In part 4 and the conclusion of this Exclusive Interview about the new diabetes classification, Dr. Schwartz highlights what he is looking forward to at the AACE and ADA conferences, particularly the results of the LEADER and GLP-1 studies.

In this week's Homerun Slides, the potential role of diabetes medications in the improved management of type 2 in older patients.

The traditional view is that islet hormone secretion is mainly regulated by circulating nutrients (glucose, amino acids, free fatty acids) as well as the gut incretin hormones (glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)). However, in certain circumstances regulation of insulin and glucagon secretion is also dependent on the autonomic nerves which innervate the islets. These nerves belong to the parasympathetic, sympathetic, and sensory branches of the autonomic nervous system.

There have been a lot of ideas over the years about making a prodrug to deliver insulin. Most of the attention has been focused on making an oral insulin. Each year we move closer, and just a few weeks ago we had information on our website about the newest of …

What should be the proper treatment selection for patients with type 2 diabetes?

Scientists believe drug commonly prescribed for T2 could be routinely taken by T1 patients.